Dear Colleagues,

Welcome to this year’s selection of EULAR abstracts on PsA and my ‘Highlights’. We have selected a variety of abstracts that cover a range of key topics in the management of psoriatic arthritis.

Wednesday starts off with an insightful series of presentations. This includes a discussion by Gonul Hazal Koc on the determinants of radiographic progression in early PsA (OP0065). The Comorbidities in RMD session also features a presentation by Daniela Di Giuseppe on the comparative effectiveness of biologic and targeted synthetic DMARDs in PsA, stratified by comorbidities (OP0022).

There are two posters of special interest to me on Thursday. This includes the latest comparison of BASDAI and ASDAS measurement tools by my CSF colleague Xenofon Baraliakos (POS0023), as well as another on enthesitis and its impact on PROs by Dennis McGonagle (POS0027).

Friday features the Treatment in psoriatic arthritis on the move session which promises to be truly interesting, featuring therapeutic updates on bimekizumab (POS0231), guselkumab (POS0227), and tofacitinib (POS0232). The latest data from the USRAT registry is also presented, discussing cardiovascular and thromboembolic events before and after the initiation of first advanced therapy (POS1063).

The Saturday EULAR Recommendations session is always important, and this year Laure Gossec presents the latest Recommendations on the management of PsA. This offers a great end to the congress, offering the latest recommendations for the management of psoriatic arthritis.

Beyond the main scientific programme there are also many interesting satellite symposia. One we suggest is the CSF’s The “Case” for JAK Inhibitors, where I will join my colleagues in discussing the optimisation of JAK inhibitor therapies. We have highlighted a selection of other symposiums at the end of this brochure.

As always, thank you for your continued support. We hope you have a fantastic time at EULAR 2023!

Kind regards

Professor Peter Nash

Ps. Make sure you get all the insights from this EULAR by downloading our other highlights brochures, and if you want to see the top picks for Lupus head on over to www.lupus-forum.com where you’ll find the top EULAR picks and their top abstracts in the field of lupus therapeutics.
Key Presentations

**Wednesday, 31 May 2023**

**16:30–18:00**
**COMORBIDITIES IN RMD**
*Chairs: Patrick Durez and Ioannis Parodis*

**OP0022**
Comparative effectiveness of biologic and targeted synthetic DMARDs in psoriatic arthritis according to comorbidities at treatment start: a Nordic collaborative study based on enriched clinical registers
*Daniela Di Giuseppe*

**16:30–18:00**
**CLINICAL ASPECTS AND TREATMENT OF AXSPA: EFFECTS AND PREDICTORS OF EFFECTS**
*Chairs: Astrid van Tubergen and Alexandre Sepriano*

**OP0061**
Development of extra-musculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis
*Denis Poddubnyy*

**16:30–18:00**
**NEW CLINICAL ASPECTS IN PSORIATIC ARTHRITIS**
*Chair: George E. Fragoulis*

**OP0062**
**EULAR points to consider for the definition of clinical and imaging features suspicious for progression to Psoriatic Arthritis**
*Alen Zabotti*

**OP0065**
**The determinants of radiographic progression in early PsA patients**
*Gonul Hazal Koc*

**OP0067**
Sex differences in perceptions of psoriatic arthritis disease impact, management and physician interactions: results from a global patient survey
*Lihi Eder*

**OP0068**
Barriers to overcome in the achievement to the treatment goal in psoriatic arthritis; central sensitization and neuropathic pain
*Servet Akar*

**Thursday, 01 June 2023**

**11:15–12:00**
**AXIAL AND PERIPHERAL SPONDYLOARTHRITIS**
*Chairs: Floris A. van Gaalen and Helena Marzo-Ortega*

**POS0024**
Management of axial and peripheral spondyloarthritis in 2023
*Desirée van der Heijde*

**12:00–13:30**
**CONTEMPORARY CLINICAL TOPICS IN PSORIATIC ARTHRITIS**
*Chair: George Bertsias*

**POS0023**
Performance of BASDAI vs. ASDAS in evaluating axial involvement in patients with PsA treated with guselkumab: pooled analysis of two phase 3 studies
*Xenofon Baraliakos*

**POS0027**
Individual entheseal points have differential frequency of involvement and impact on patient reported outcomes in patients with active psoriatic arthritis: pooled analysis of two phase 3, randomized, double-blind, placebo-controlled studies
*Dennis McGonagle*

**Friday, 02 June 2023**

**09:30–10:30**
**POSTER VIEW 4**

**POS1063**
Cardiovascular and thromboembolic events in rheumatoid arthritis and psoriatic arthritis patients over 3 years before and 3 years after initiation of a first advanced therapy. data from the university of sherbrooke registry of advanced therapies (USRAT)
*Gilles Boire*

**11:15–12:00**
**HOW TO TREAT PSORIATIC ARTHRITIS**
*Chair: Denis Poddubnyy*

**POS0224**
How Well Does Ultrasound-Assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
*Maria-Antonietta D’Agostino*

**POS0227**
Serum extracellular matrix biomarkers identify response to guselkumab in psoriatic arthritis: post-hoc analysis from a phase 3, randomized, double-blind, placebo-controlled study through 2 years
*Signe Hohn Nielsen*

**POS0228**
Minimal important difference (MID), minimal detectable change (MDC), and disease activity thresholds for two novel composite instruments (3VAS, 4VAS) in patients with psoriatic arthritis: pooled analysis of three phase 3 studies
*William Tillett*

**POS0231**
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: results from the phase 3 be complete study and its open-label extension up to 1 year
*Joseph F. Merola*

**POS0232**
Post-marketing safety surveillance of tofacitinib over 9 years in patients with rheumatoid arthritis and psoriatic arthritis
*Gerd Rüdiger Burmester*
Saturday, 03 June 2023

10:30 – 11:30  POSTER VIEW 6

POS1528  Prediction Of Low Disease Activity In Patients With Psoriatic Arthritis Treated With Secukinumab In Real World – Data From The German Aquila Study
Uta Kiltz

POS1533  Bimekizumab Treatment Resulted In Clinically Meaningful Improvements In The Psoriatic Arthritis Impact Of Disease-12 (Psaid-12) Scores Using Pooled Results From Two Phase 3 Trials In Patients With Psoriatic Arthritis
Laure Gossec

POS1534  Bimekizumab Maintained Efficacy Responses Through 52 Weeks In Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Psoriatic Arthritis Who Were Responders At Week 16: Results From Be Optimal, A Phase 3, Active-Reference Study
Dennis McGonagle

POS1536  Assessment Of Pain Outcomes In A Phase 2 Trial Of Deucravacitinib In Patients With Active Psoriatic Arthritis
Philip J. Mease

POS1537  Bimekizumab Efficacy And Safety In Biologic Dmard-Naive Patients With Psoriatic Arthritis Was Consistent With Or Without Methotrexate: 52-Week Results From The Phase 3 Active Reference Study Be Optimal
Frank Behrens

POS1538  Safety And Efficacy Of Upadacitinib In Patients With Psoriatic Arthritis And Inadequate Response To Biologics: 3-Year Results From The Phase 3 Select-Psa 2 Study
Philip J. Mease

POS1540  Early Skin And Early Enthesitis Responses In Psoriatic Arthritis Patients Treated With Guselkumab Associate With Long-Term Response: Post Hoc Analysis Through 2 Years Of A Phase 3 Study
Dennis McGonagle

POS1541  Long-Term Efficacy And Safety Of Upadacitinib In Patients With Psoriatic Arthritis: 3-Year Results From The Phase 3 Select-Psa 1 Study
Iain McInnes

POS1544  Long-Term Safety And Efficacy Of Tofacitinib In Patients With Psoriatic Arthritis By Prior Biologic Disease-Modifying Antirheumatic Drug Exposure
Dafna D Gladman

12:00 – 13:15  EULAR RECOMMENDATIONS SESSION

Chairs: Robert B.M. Landewé and Uta Kiltz

EULAR-recommendations on the management of PsA
Laure Gossec

RHEUMATOID ARTHRITIS – NON BIOLOGIC TREATMENT AND SMALL MOLECULES

AB0450  Real-World Use Of Jak Inhibitors in Rheumatological Practice in South London
K. Biddle

SPONDYLOARTHRITIS – TREATMENT

AB0938  Safety Profile of Bimekizumab at Week 16 In Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Four Placebo-Controlled Phase 3 Studies
D. Podubravny

AB0957  Improvements In Patient-Reported Outcomes Among Patients with Resolution of Enthesitis And/Or Dactylitis: Post Hoc Analyses From The Keepsake 1 And 2 Trials of Risankizumab in Patients with Active Psoriatic Arthritis
S. Kwatra

AB0959  Secukinumab Survival and Associated Demographic Characteristics in Patients with Spondyloarthritis and Psoriatic Arthritis in A Real Clinical Setting
M. López I Gómez

PSORIATIC ARTHRITIS – TREATMENT

AB1082  Early Clinical Response as A Predictor of Long-Term Health-Related Quality of Life Improvements in Patients with Psoriatic Arthritis and Tnfi-Ir Receiving Guselkumab (Cosmos)
L. Gossec
AB1084
Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
J. Curtis

AB1087
Long-Term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients with Active Psoriatic Arthritis
D. D. Gladman

AB1088
Early Clinical Improvement as Predictor of Long-Term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post-Hoc Analysis Through 2 Years of A Phase-3 Study
I. McInnes

AB1089
Bimekizumab Efficacy in High-Impact Areas for Patients with Moderate to Severe Plaque Psoriasis: Pooled Results Through Two Years from The Be Sure and Be Radiant Phase 3 Trials
J. F. Merola

AB1090
Efficacy Of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-Bearing Joint Regions: A Post Hoc Subgroup Analysis of The Phase 3, Randomized, Select-Psa 1 And Select-Psa 2 Trials
K. Mizelle

AB1092
Guselkumab Rapidly Improves Activities of Daily Living in Patients with Active Psa: Pooled Analysis Of 2 Phase 3, Randomized, Placebo-Controlled Studies
P. Rahman

AB1093
Long-Term Improvement in Individual ACR Response Criteria and Residual Disease in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Of A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
P. Nash

AB1094
Guselkumab Effect on Inflammatory Cardiovascular (CV) Risk Biomarkers, Efficacy, And Safety in Psoriatic Arthritis Patients with CV Risk Factors: Post-Hoc Analysis Of 2 Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
A. Kavanagh

AB1096
Improvement In Key Psoriatic Arthritis Core Domains with Guselkumab Treatment in An Enriched Population of Acrt20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
D. McGonagle

AB1097
Malignancies With Long-Term Use of bimekizumab in Adults with Psoriasis, Psoriatic Arthritis, Or Axial Spondyloarthritis: A Post-hoc Analysis of Data From 25 Randomized Clinical Trials
M. Lebwohl

AB1098
Deucravacitinib In Plaque Psoriasis: 2-Year Laboratory Results From The Phase 3 Poetryk Pso Program
N. J. Korman

AB1099
Sustained Efficacy of Bimekizumab Treatment Assessed Using Composite Disease Activity Measures in Patients with Psoriatic Arthritis and Prior Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors: Results from The Phase 3 Be Complete Study and Its Open Label Extension Up To 1 Year
L. Coates

AB1103
Upadacitinib Real-Life Efficacy and Safety in Psoriatic Arthritis: Results At 24 Weeks Of A Multicentric Italian Study (Up-Real)
V. Paci

AB1105
Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, Or Axial Spondyloarthritis: A Post-Hoc Analysis Of End-Of-Study Program Data Relating To Major Adverse Cardiovascular Events
M. Lebwohl

AB1106
Efficacy Of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review And Meta-Analysis
H. Zhou

AB1108
Effect Of Guselkumab Administered Every 8 Weeks in Patients with Active Psoriatic Arthritis Persisting Between Consecutive Doses and Is Durable: Post Hoc Analysis of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
P. J. Mease

AB1109
Treatment Retention and Safety of Ixekizumab in A Population with Psoriatic Arthritis Refractory to Biologic and Targeted Synthetic DMARDs
I. Braña Abascal

AB1111
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, And Medication Characteristics in Patients with Active Psoriatic Arthritis and An Inadequate Response to TNF Inhibitors: Results from A Phase 3b Trial
I. McInnes

AB1112
Description of the Real-World Treatment Patterns of Guselkumab in The Management of Psoriatic Arthritis in Australia: An Analysis from The Opal Dataset
G. Littlejohn

AB1119
Guselkumab Efficacy and Safety Analysis for Psa According to Baseline Demographics, Disease, And Medication Characteristics in Patients with Active Psoriatic Arthritis: A Post-Hoc Analysis Of Synarcus Dose Levels In The Management of Psoriatic Arthritis With Synthetic DMARDs With Active Psoriatic Arthritis Refractory to Biologic and Targeted Synthetic DMARDs
I. McInnes

AB1120
Real-Life Efficacy and Safety of Ixekizumab in A Cohort of Patients with Psoriatic Arthritis: A Single-Center Retrospective Study
E. Bellis

AB1122
Guselkumab Vs Golimumab in Psa Trni-Inadequate Responders (Evolution): Formulating A Pragmatic Phase 3b Randomized Trial
A. Ogdie

AB1123
Efficacy And Safety of Secukinumab in Patients with Psoriasis
Q. Y. Su

AB1124
Tofacitinib In Psoriatic Arthritis -Well Tolerated Drug — Real Life Experience
V. Petciappan

AB1125
Treatment With Upadacitinib in Refractory Psoriatic Arthritis.
Multicenter Study Of 101 Patients of Clinical Practice
E. Galíndez-Agirregoikoa